Filing Flows › Biolife Solutions (BLFS) › Q3 2025
Biolife Solutions (BLFS) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Biolife Solutions (BLFS) reported revenue of $28.1M for the third quarter 2025 (Q3 2025), +31% from a year earlier and +10% from the quarter before. Operating margin was -0.3%, net earnings $621K (2.2% of revenue).
Biolife Solutions, Q3 2025: revenue $28.1M (+31% year over year), operating margin -0.3%, net earnings $621K, operating cash flow $6.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $28.1M | +10% | +31% |
| Operating profit | −$89K | — | — |
| Net earnings | $621K | — | — |
| Operating cash flow | $6.1M | -17% | +27% |
| Free cash flow | $5.7M | +2% | +15% |
What changed
Revenue was $28.1M in Q3 2025, up 31% year over year and up 10% from the previous quarter. Cell processing was the largest line at 90% of revenue. Cell processing added $6.3M year over year (up 33%), 94% of the total change.
Operating costs exceeded revenue by $89K, an operating margin of -0.3%. Total costs grew 29% against revenue growth of 31%. The fastest-growing cost line was Research & development (+43%). Net earnings were $621K. The effective tax rate was 11.7%. Non-operating items added $792K, 113% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $6.1M (up 27% year over year), 983% of net earnings. Non-cash charges added back $636K of depreciation and amortization and $5.9M of share-based compensation. Working capital and other items used $1.1M. Capital expenditures of $360K left free cash flow of $5.7M.
Questions
What was Biolife Solutions' revenue in the third quarter 2025?
Biolife Solutions (BLFS) reported revenue of $28.1M for the third quarter 2025 (Q3 2025), +31% from a year earlier and +10% from the quarter before.
Was Biolife Solutions profitable in the third quarter 2025?
Operating loss was $89K (-0.3% of revenue) and net earnings $621K.
Source: Biolife Solutions 10-Q on SEC EDGAR.